



**Contact:**

Dr. Misha Plam

President & CEO

T: (303) 641-3669

[misha.plam@amidebio.com](mailto:misha.plam@amidebio.com)

[www.amidebio.com](http://www.amidebio.com)

**AmideBio Obtains Core Patent for Peptide Production Platform Technology**

**BOULDER, CO, August 20, 2014** – AmideBio, LLC, a privately held biopharmaceutical company, announced today that the U.S. Patent and Trademark Office (USPTO) has issued United States Patent 8,796,431, “Efficient Production of Peptides”. The patent provides broad coverage of the Company’s core platform technology: its efficient and green Biopure™ peptide manufacturing process. The Biopure process facilitates rapid structure activity relationship (rSAR) studies on high value peptide therapeutics and lowers the downstream production costs for difficult to manufacture peptides. The company has already leveraged this platform technology in several high value areas, including the production and initial evaluation of a large library of thermostable Insulins, several next generation diabetes product candidates, and the production of highly pure amyloid peptides for research in Alzheimer’s Disease.

“Issuance of this U.S. patent represents a key milestone for AmideBio. We expect that it will be the first of many patent issuances covering aspects of our core Biopure platform technology as well as classes of peptides that we are developing for the research and commercial markets,” said Dr. Misha Plam, AmideBio’s President and CEO. “Our initial research focus has been on novel Thermostable Insulins and other peptides for the treatment of diabetes and on amyloid peptides for the study of Alzheimer’s. The breadth of our platform will allow us to pursue these and other peptides having both medical and commercial significance, and we are actively pursuing potential partnership and license arrangements with pharmaceutical and biotechnology companies.”

The technology was developed under the scientific leadership of Dr. Michael Stowell, Associate Professor of MCD Biology and Mechanical Engineering at the University of Colorado, and the Company’s CTO and founder. The University has exclusively licensed its rights in the technology to AmideBio. “We are delighted to see the issued patent on Dr. Stowell’s invention,” said Kate Tallman, Interim Associate Vice President of Technology Transfer at CU. “AmideBio has put enormous effort into perfecting the process and developing the strategic relationships necessary to take it to market.”

**About AmideBio:**

AmideBio, based in Boulder, CO, is a biotechnology company leveraging its proprietary BioPure™ platform technology to deliver difficult-to-manufacture peptides and build a pipeline of novel biotherapeutics. AmideBio's proprietary technology enables the rapid and economical manufacture of pure peptides of any length. This innovative technology combines recombinant and chemical methods, eliminates many of the inefficient and costly steps of processes that rely only on one or the other approach, results in fewer batch inconsistencies and less waste generation. Such advantages enable AmideBio to offer its cost-efficient technology and peptide product candidates to the pharmaceutical and biotech industry. The Company continues to expand its proprietary technology platform in the areas

of protein production, biosimilar therapeutic manufacturing and internal research and development of novel biotherapeutics aimed at metabolic, inflammatory and neurodegenerative diseases.

- ENDS -